Vulnerability · CVE-2025-36228
IBM Aspera Faspex 5 5.0.0 through 5.0.14.1 may allow inconsistent permissions between the user interface and backend API allowed users to access features that appeared disabled, po
Published Dec 26, 2025 · catalog updated Dec 26, 2025 · IBM Aspera Faspex 5
Last checked Nov 2, 2026. A connected source was read within the last 7 days.
Check if you run it
No confirmed exploitation is on record for CVE-2025-36228. EPSS is 0.22%. Act only if a listed version of IBM Aspera Faspex 5 is installed.
Gaps on this record
- No vendor fix or required action is stored. Compare the linked advisory before you change production.
Same product and reporting
- CVE-2025-36230 · Medium
- CVE-2025-36229 · Low
- Severity
- Low3.8
- Known exploitation
- Not in CISA/VulnCheck KEV
- EPSS
- 0.22%
- Remediation
- Vendor / distro source
- Affected products
- vendor IBM Aspera Faspex 5 5.0.0 ≤5.0.14.1
IBM Aspera Faspex 5 5.0.0 through 5.0.14.1 may allow inconsistent permissions between the user interface and backend API allowed users to access features that appeared disabled, potentially leading to misuse.
Are you affected?
Enter the version you run. The result uses only the ranges stored on this record.
The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.
- vendor IBM Aspera Faspex 5 5.0.0 ≤5.0.14.15.0.0 ≤5.0.14.1
How to fix CVE-2025-36228
No stored fix
No vendor fix text is stored. Use the linked advisory before you change production.
Version check
Seen in 5.0.0 ≤5.0.14.1
Advisory
Open the cve_org record and follow its fix.
Official advisories
What to do
Three questions, each answered from this record only. Confirm the vendor advisory before you patch.
Should you patch?
No confirmed exploitation is on record for CVE-2025-36228. EPSS is 0.22%. Act only if a listed version of IBM Aspera Faspex 5 is installed.
Which versions are affected?
Compare what you have installed with IBM Aspera Faspex 5 5.0.0 ≤5.0.14.1 5.0.0 ≤5.0.14.1. Compare the installed version with the linked vendor advisory before you change production.
What should an analyst verify?
No weakness class is stored. EPSS 0.22%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.
Code
The project this record applies to. Exploit listings stay in References.
No public source repository is identified for this product.
Timeline
Detection, updates, and resolution for this record.
Dec 26, 2025 · EUVD
Detected
IBM Aspera Faspex 5 5.0.0 through 5.0.14.1 may allow inconsistent permissions between the user interface and backend API allowed users to access features that appeared disabled, potentially leading to misuse.
Dec 26, 2025 · EUVD
Updated
IBM Aspera Faspex 5 5.0.0 through 5.0.14.1 may allow inconsistent permissions between the user interface and backend API allowed users to access features that appeared disabled, potentially leading to misuse.
Sources
- CVE.orgVulnerability recordCVE-2025-36228
Official CVE identifier
cve.org - FIRST EPSSExploitation probabilityCVE-2025-36228
30-day exploitation probability 0.22%
first.org - EUVDVulnerability recordEUVD-2025-205441
IBM Aspera Faspex 5 5.0.0 through 5.0.14.1 may allow inconsistent permissions between the user interface and backend API allowed users to access features that appeared disabled, potentially leading to misuse.
euvd.enisa.europa.eu
References
Freshness
Last verified in this catalog Nov 2, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.
- FIRST EPSSNov 2, 2026
- CVE.orgNov 2, 2026
- EUVDNov 1, 2026